Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359628 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29709949 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL3663656 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29636980 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL121431 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL586622 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL15866526 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL3723159 | 0.93 | ELANE (0.87) | ELANECYP3A4CYP2C9 | |
| SCHEMBL2117084 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL122824 | 0.93 | ELANE (0.87) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4585223-A2 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | The Regents of the University of California (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12247032-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases | GENENTECH, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119523956-A | Application of marimastat in preparation of medicine for promoting skin stretch regeneration | 上海交通大学医学院附属第九人民医院 | 2025-02-28 | — | — | CN | disclosed |
| CN-114026096-B | Tetrazole-substituted pyrazolopyrimidine JAK kinase inhibitor and application thereof | 豪夫迈·罗氏有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114008050-B | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | MEREO BIOPHARMA 4 LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| EP-4419102-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Mereo Biopharma 4 Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-114008051-B | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118265527-A | Neutrophil elastase inhibitors for the treatment of fibrosis | 美莱奥生物制药第四有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-109890817-B | 8- (azetidin-1-yl) - [1,2,4] triazolo [1,5-a ] pyridinyl compounds, compositions, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-110494434-B | Pyrazolophenyl compounds, compositions thereof, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3986901-A1 | PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986899-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986900-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20220106322-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| CN-109970743-B | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114008051-A | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106322-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | JAK2, JAK1, JAK3 | ELANE 1491/4885CYP3A4 1651/4885CYP2C9 1339/4885 |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | SERPINB1, ELANE, MMP8 | ELANE 2/4885CYP3A4 2916/4885CYP2C9 2725/4885 |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | ELANE 3577/4885CYP3A4 2186/4885CYP2C9 1927/4885 |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | ELANE 418/4885CYP3A4 2135/4885CYP2C9 3166/4885 |
| US-12247032-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases | JAK1, JAK2, JAK3 | ELANE 3736/4885CYP3A4 2137/4885CYP2C9 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.